Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Likarda, Inc. logo — Transforming How Cell Therapies, Biologics, Peptides, and Ho...

Likarda, Inc.

Transforming How Cell Therapies, Biologics, Peptides, and Hormones Are Delivered

Founded 2012 United States Kansas City, United States 14 employees Total: $4.60M Biotechnology, Health and Wellness +1

General Information

Company Name Likarda, Inc.
Founded Year 2012
Location United States Kansas City, United States
Employees 14
Industries Biotechnology, Health and Wellness, Industrial
Business Model B2B, D2C, Platform
Revenue Model Licensing, Service Fee, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Likarda, Inc.. To contact Likarda, Inc., visit likarda.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Likarda, Inc.

Likarda, Inc., founded in 2012, is a U.S.-based biotech company, innovating in the delivery of cell therapies through its proprietary technology, Core Shell Spherification® (CSS). This method employs stealth hydrogels to ensure therapeutic cells remain viable and effective within the targeted area of the body.

The company distinguishes itself with a library of over 50 unique hydrogel formulations, providing tailored solutions optimized for specific therapeutic applications. Likarda's approach offers both durable and degradable coatings, addressing varying delivery timeframes, from days to months.

Recently securing an Early VC investment on February 1, 2024, from the Missouri Technology Corporation (MTC), Likarda continues to push technological boundaries under visionary leadership, with plans for flexible growth in the Biotechnology and Health and Wellness sectors.

Taxonomy: Cell Therapy Delivery, Hydrogel Formulations, Core Shell Spherification, Biocompatible Coatings, Cell Encapsulation, Immunoprotective Barriers, Injectable Cell Therapies, Diabetes Treatment, Osteoarthritis Treatment, Microencapsulation Technologies, Regenerative Medicine, Biotechnology Innovations, Therapeutic Cell Preservation, Slow-Release Drug Formulation, Preclinical Testing

Services & Products

Core-Shell Spherification
Cell-based Encapsulation Systems
Cryopreservation Solutions
Hydrogel Delivery Platforms
Therapeutic Customization Consultations

Target Customers

Biotech Companies Pharmaceutical Companies Research Organizations Healthcare Providers

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC Undisclosed 1
Missouri Technology Corporation (MTC)
Missouri Technology Corporation (MTC)
01 Feb 2024
Series A $4.00M 1
Werth Family Investment Associates
01 Aug 2017
Seed $600.00K -
01 Aug 2012

Likarda, Inc. Alternatives & Competitors

View All Alternatives
Likarda, Inc. vs
ViaCyte
ViaCyte United States

Regenerating Health: Transforming the lives of patients with insulin-requiring diabetes

Series D
35 employees
Biotechnology, Health Care
Likarda, Inc. vs
Serina Therapeutics, Inc.
Serina Therapeutics, Inc. United States

We have the next generation in polymer therapeutics. Go to www.serinatherapeutics.com and explore ou...

Grant
15 employees
Biopharma, Biotechnology
Likarda, Inc. vs
Wheeler Bio, Inc.
Wheeler Bio, Inc. United States

CMC Made for Biotechs

Series A
76 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Likarda, Inc.

Transforming How Cell Therapies, Biologics, Peptides, and Hormones Are Delivered
Likarda, Inc. was founded in 2012.
Likarda, Inc. is headquartered in Kansas City, United States.
Likarda, Inc. operates in Biotechnology, Health and Wellness and Industrial. Its work centres on Cell Therapy Delivery, Hydrogel Formulations, Core Shell Spherification and Biocompatible Coatings. Its customers include Biotech Companies, Pharmaceutical Companies and Research Organizations.
Likarda, Inc. has a B2B, D2C and Platform business model. Its revenue comes from Licensing, Service Fee and Product Sales.
Likarda, Inc. has approximately 14 employees.
Likarda, Inc. has completed 3 funding rounds, raising a total of $4.60M.
Likarda, Inc. offers: Core-Shell Spherification, Cell-based Encapsulation Systems, Cryopreservation Solutions, Hydrogel Delivery Platforms, Therapeutic Customization Consultations.
Top alternatives and competitors to Likarda, Inc. include ViaCyte, Serina Therapeutics, Inc., Wheeler Bio, Inc., Manifold Bio, KSQ Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Likarda, Inc. and ViaCyte are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Likarda, Inc., https://bouncewatch.com/company/likarda, updated 27 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes